Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches
Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches
复制标题
从系统生物学角度探讨冠心病血瘀证的生物医学机制
DOI：
10.1007/s11655-013-1461-3
复制
发表时间：
2014-03-01
影响因子：
2.9
通讯作者：
Yu Gui
中科院分区：
文献类型：
--
作者：
Wang Jie;Yu Gui
冠心病的患病率日益增加，已成为全世界社会和家庭的严重负担。因此，需要有新的思路来开发更有效和安全的治疗冠心病的方法。中医药根据患者的不同证候，采用多组分药物来预防疾病和改善症状。CM在CHD中的益处最近已被越来越多的临床证据证明。更重要的是，中医辨证与生物医学诊断相结合，可能为冠心病的治疗提供新的思路。流行病学调查显示，血瘀证是冠心病的主要证型。探讨冠心病血瘀证的生物医学机制是中医药研究的热点之一。由于系统生物学的整体观点与CM很好地匹配，组学技术和其他综合方法的应用似乎是天生合适的。广泛的组学技术，包括转录组学和蛋白质组学，已被用于冠心病BSS的研究，以寻求共同的理解基础。这些方法可能有助于从临床和生物学角度理解CHD的BSS。然而，目前的研究主要是从单一的方法得到的结果，没有达到系统生物学的整体、系统和综合的概念。本文就系统生物学方法在冠心病血瘀证生物医学机制研究中的进展和面临的挑战作一综述。随着系统生物学的进一步发展，将为冠心病血瘀证的研究提供更好的平台，寻找冠心病血瘀证的生物标志物和治疗靶点，并为冠心病血瘀证的个体化治疗提供有益的借鉴。
The prevalence of coronary heart disease (CHD) is increasing, and has been a severe burden on society and family worldwide. New ideas need to be achieved for developing more efficacious and safe therapies to treat CHD. Chinese medicine (CM) uses multicomponent drugs to prevent disease and ameliorate symptoms based on patients' different syndromes. The benefit of CM in CHD has recently been proven by increasing clinical evidence. More importantly, linking CM syndrome differentiation and biomedical diagnosis might provide innovative thinking for treating CHD. According to epidemiological investigations, blood stasis syndrome (BSS) is the major type of syndrome in CHD. Investigating the biomedical mechanisms of BSS of CHD is a topic of CM research. Because the holistic perspective of systems biology is well matched with CM, the application of omics techniques and other integrative approaches appears inherently appropriate. A wide range of omics techniques, including transcriptomics and proteomics, have been used in studies of BSS of CHD to search for a common ground of understanding. These approaches could be useful for understanding BSS of CHD from clinical and biological viewpoints. Nevertheless, current studies mainly contain results from a single approach, and they have not achieved the holistic, systematic and integrative concept of system biology. Therefore, we discuss the progress and challenges in exploring the biomedical mechanisms of BSS of CHD by systems biology approaches. With further development of systems biology, a better platform to study BSS of CHD may be provided, and biomarkers for BSS of CHD and therapeutic targets may be found. The study of BSS of CHD by systems biology approaches will also be beneficial for developing personalized treatment for BSS of CHD patients.